Strongest human evidence The METAOD006 (OPTIONS) Phase 2b trial randomized 502 adults with obesity (BMI 30-45 kg/m^2) to oral AOD-9604 (0.25, 0.5, or 1 mg/day) or placebo for 24 weeks alongside a supervised diet and exercise program
Although clinical trials specifically for MASH have not yet been conducted, preclinical studies confirm significant regulatory effects on hepatic metabolism, providing a novel strategy for targeted MASH therapy and supporting future translational research
What This Program Supports|Cellular energy production and metabolism
GHK-Cu is a copper-binding tripeptide (glycyl-L-histidyl-L-lysine) studied in cell and animal models for collagen synthesis, angiogenesis and skin remodelling [1]
Obeid R, Andrs E, eka R, Hooshmand B, Guant-Rodriguez RM, Prada GI, Sawek J, Traykov L, Ta Van B, Vrkonyi T, Reiners K, The Vitamin B Consensus Panelists Group